The study was designed as a 12-month prospective observational study of 131 subjects with schizophrenia or related disorders treated with haloperidol, olanzapine, risperidone, quetiapine, or aripiprazole, recruited from consecutive hospitalized patients in a psychiatry department. Results:The mean scores for patients' reported quality of life and its components and for satisfaction with treatment had a favorable evolution, but increases were of reduced magnitude. The differences among treatment groups were not statistically significant, with few exceptions. A great variability of data was found. Conclusion:Studies with a stratified analysis by factors influencing quality of life perceptions in this category of patients might allow the identification of differences, if any, between antipsychotics in this domain.